|
Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome |
Gates S, Perkins G, Lamb S, Kelly C, Thickett D, Young D, McAuley D, Snaith C, McCabe C, Hulme C, Gao-Smith F |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Gates S, Perkins G, Lamb S, Kelly C, Thickett D, Young D, McAuley D, Snaith C, McCabe C, Hulme C, Gao-Smith F. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technology Assessment 2013; 17(38) Original Paper URL http//journalslibrary.nihr.ac.uk/ememrc/hta17380 Indexing Status Subject indexing assigned by NLM MeSH APACHE; Adolescent; Adrenergic beta-2 Receptor Agonists /adverse effects /economics /therapeutic use; Adult; Age Factors; Aged; Aged, 80 and over; Albuterol /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; Double-Blind Method; Female; Great Britain; Hospital Mortality; Humans; Infusions, Intravenous; Intensive Care Units /statistics & Length of Stay; Male; Middle Aged; Respiration, Artificial; Respiratory Distress Syndrome, Adult /drug therapy /mortality; Young Adult; numerical data AccessionNumber 22013052632 Date bibliographic record published 20/12/2013 |
|
|
|